The One Health approach recognizes the close links between the health of humans, animals, plants and the environment. Due to this holistic view of health, the approach places special demands on researchers. The aim of the One Health Platform is to support researchers in the implementation of One Health and to improve the framework conditions for this. To this end, it actively promotes inter- and transdisciplinary networking, awards research funding, supports young scientists and advocates the One Health approach in science, politics and the public.
We are therefore grateful that – also thanks to the financial support of the Federal Ministry of Research, Technology and Space, Pfizer, Promega and Macherey-Nagel – we can bring together about 400 scientists from different disciplines through this event: senior scientists, postdocs, PhD students, graduate students, public health workers, undergraduate students. With nearly 160 abstracts on the ten topics, there is the opportunity for the submitters to present their work either in one of the coveted short talks or as a poster, in the permanently accessible poster exhibition.
Funding
Sponsoring
Pfizer (€ 3.250) • Promega (€ 3.250) • Macherey-Nagel (€ 3.000)
At Pfizer, we work every day around the world to improve people's quality of life by giving them access to innovative medicines and vaccines. We do this through science and our global network of research, development, manufacturing and distribution centers. Our aim is to set new standards in the discovery, development and manufacture of innovative medicines. This applies to their quality, their safety and their benefits for patients. In both industrialized and emerging countries, our colleagues are driving the prevention, treatment and cure of the most serious diseases of our time. As one of the world's leading research-based pharmaceutical companies, we partner with healthcare professionals, healthcare institutions, government organizations and local communities around the world to promote reliable and affordable healthcare. For more than 175 years, we have worked to make a difference for all who rely on us.
Pfizer is headquartered in New York. In Germany, more than 3,000 employees work at our sites in Berlin, Freiburg and Karlsruhe. Our plant in Freiburg is one of the most modern pharmaceutical production facilities in the world and Pfizer's largest for tablets and capsules. It is a pioneer in sustainability and Industry 4.0.
For over 45 years, Promega has been a trusted partner in life science research and diagnostics, providing innovative molecular biology solutions for gene, protein, and cell analysis. Building on this expertise, we are committed to advancing One Health—recognizing that human, animal, and environmental health are deeply interconnected.
Our Maxwell® instruments automate nucleic acid purification from clinical, veterinary, environmental, and food samples, delivering high-quality DNA and RNA while standardizing workflows across diverse applications. For downstream analysis, GloMax® and Quantus™ provide sensitive signal quantification for pathogen detection, immune response analysis, and biomarker measurement, supporting infectious disease surveillance as well as environmental and food safety monitoring. The Spectrum Compact CE System further extends these capabilities by offering accessible Sanger sequencing and fragment analysis for laboratories across the One Health landscape.
Together, these solutions enable researchers, diagnostic laboratories, and regulatory agencies to generate reliable results and make informed decisions with confidence. By supporting applications across human, animal, and environmental health, Promega is helping to advance the One Health approach and contribute to a healthier, safer world for everyone.
MACHEREY-NAGEL was founded in 1911 as a specialist manufacturer of filter papers in Düren. Since then, the company has evolved into an innovative, globally active provider of chemical and biomolecular analysis. It is currently managed by the fourth generation of the founding family and employs over 700 people. With five locations in Düren and subsidiaries in the USA, Switzerland, and France, MACHEREY-NAGEL offers more than 25,000 products in over 150 countries. The company has found significant success in its newest product area, bioanalytics, since 1994 and produces its own kit systems for efficient RNA, DNA, and protein purification. These kits are used in industrial biotechnology, the pharmaceutical industry, environmental analysis, forensics, academic research, and healthcare, among other fields. During the COVID-19 pandemic, MACHEREY-NAGEL's extensive portfolio played a crucial role in the diagnosis and management of COVID-19. For instance, the company is currently involved in studies on wastewater diagnostics that allow for early detection of COVID-19 infection rates. The high quality of its products is demonstrated by numerous patents and international certifications. MACHEREY-NAGEL represents a company with tradition and a promising future. It offers high-quality products “Made in Germany” and is known as a trusted and reliable partner in science and medicine.
